AAD to launch Listen To Your Skin, Educate about Actinic Keratosis

Although more than 50 million Americans have a skin condition called actinic keratosis (AK), which may progress to skin cancer, many don’t know they have it.

Download image PARSIPPANY, N.J., Feb. 15, 2012 /PRNewswire/ — The American Academy of Dermatology (AAD) and LEO Pharma want Americans to know that sunburns and premature aging aren’t the only indications that their skin has been damaged by cumulative exposure to the sun. Research-based pharmaceutical company LEO Pharma has partnered with the AAD to launch Listen To Your Skin, a campaign aimed to raise awareness about the consequences and symptoms of cumulative sun damage including actinic keratosis (AK), a precancerous condition, and skin cancer. The campaign’s first initiative is an informational website,www.listentoyourskin.org, where visitors can discover more about AK and sun damage, view photos of AK and skin cancers, and find out how to check their own skin for AK and other signs of sun damage.

“Many people are aware of the connection between melanoma and moles, but many Americans who may be at risk for skin cancer are unaware of actinic keratoses, what they look like, how to detect them and their relationship to skin cancer,” says dermatologist Ellen Marmur, M.D., F.A.A.D., spokesperson for the AAD. “In fact, nonmelanoma skin cancers make up the vast majority of skin cancers diagnosed each year. We’re launching this initiative specifically to raise awareness about actinic keratoses and nonmelanoma skin cancer, and help Americans understand who is at risk and how AKs can be detected.”

While many Americans are aware that severe sunburns can lead to sun damage and skin cancer, sun exposure over the course of many years also contributes to significant sun damage. AK is a common precancerous skin condition caused by cumulative UV exposure. Sometimes called “sun spots” or mistaken for age spots, these often rough or scaly patches can be red, pink, gray or skin-colored and often appear on sun-exposed areas like the face, neck, and scalp.[i] It is estimated that AK currently affects up to 58 million Americans[ii], and the number of patients is growing, with the AAD estimating that 60 percent of predisposed persons older than 40 have at least one AK. People who are predisposed to developing AK tend to have fair skin, sunburn easily or have occupations or hobbies that result in excessive sun exposure.[iii]

AK has the potential to progress to squamous cell carcinoma, the second most common type of skin cancer. One in five Americans will develop skin cancer in the course of their lifetime.[iv]

LEO Pharma and the AAD have partnered to raise awareness about the prevalence of sun damage among Americans and the lesser known signs, symptoms and consequences of overexposure to the sun, including AK and squamous cell carcinoma. While many Americans know to check for suspicious moles and are aware of the risk of melanoma associated with sun damage, this campaign aims to get Americans to listen to their skin and what it may be telling them about their lifetime sun exposure and risk of skin cancer. To find out more about AK, skin cancer and how to listen to your skin, see your dermatologist and visit www.listentoyourskin.org.

[i] “Actinic Keratosis.” Medline Plus. National Library of Medicine and National Institute of Health, updated October 8, 2010. Accessed December 01, 2011. <http://www.nlm.nih.gov/medlineplus/ency/article/000827.htm>.

[ii] Lewin Group. Burden of Skin Diseases. 2005. Prepared for The Society for Investigative Dermatology and the American Academy of Dermatology Association. Accessed December 01, 2011. <http://www.lewin.com/content/publications/april2005skindieases.pdf>

[iii] Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995;32:95-8.

[iv] Robinson JK. Sun Exposure, Sun Protection, and Vitamin D. JAMA 2005; 294: 1541-43.

SOURCE LEO Pharma

Research on Major Allergen from House Dust Mite : Author Interview

Retagging Identifies Dendritic Cell-specific Intercellular Adhesion Molecule-3 (ICAM3)-grabbing Non-integrin (DC-SIGN) Protein as a Novel Receptor for a Major Allergen from House Dust Mite

Author Interview: Amir Ghaem-Maghami   MD, PhD

Associate Professor in Immunology
Course Director for MSc in Immunology & Allergy
Immunology, School of Molecular Medical Sciences
Queen’s Medical Centre Nottingham University

What are the main findings of the study?

In this study we have found a new mechanism for the uptake of major allergens from house dust mite and dog by human antigen presenting cells that involves a protein called DC-SIGN.

Were any of the findings unexpected?

The uptake of allergens by DC-SIGN was not unexpected. However, we were a bit supersized by discovering that allergen-DC-SIGN interaction seems to dampen rather than promote  allergic responses.

What should clinicians and patients take away from this study?

This is another step towards better understanding of early events at the interface of allergens with our immune system. If we know how allergens are recognised by our innate immune cells and what receptors are involved then we can design better and more efficient treatment strategies that can target early stages of allergic sensitization.

What recommendations do you have for future research as a result of your study?

Specific Immunotherapy for allergic diseases (also known as allergy vaccines) have proven to be efficient in many patient groups. Our finding could for example help with the design of  more efficient vaccines that target DC-SIGN rather than other pro-allergic receptors on antigen presenting cells. This could be done by ‘engineering’ sugars on the surface of allergens that are used in allergy vaccines.

Reference:

Retagging identifies dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) as a novel receptor for a major allergen from house dust mite.

Emara M, Royer PJ, Mahdavi J, Shakib F, Ghaemmaghami AM.
University of Nottingham, United Kingdom
J Biol Chem. 2011 Dec 28. [Epub ahead of print]

Comparative studies of stratum corneum integrity benefits of two cosmetic niacinamide/glycerin body moisturizers vs. conventional body moisturizers.

Two randomized, controlled, comparative studies of the stratum corneum integrity benefits of two cosmetic niacinamide/glycerin body moisturizers vs. conventional body moisturizers.

Author Interview: Frannie Marmorstein

Assistant Account Executive

What are the main findings of the study?

These studies found the two body moisturizers containing a niacinamide/glycerin formula, Olay® Advanced Healing Lotion and Olay® Ultra Moisture Lotion, had significant advantages versus a number of competitive moisturizers in two key areas: improving skin barrier over time and rapidly hydrating skin. The two niacinamide/glycerin moisturizers demonstrated an overall better solution towards rapid and prolonged improvement of dry skin due to their functional improvement of skin barrier function compared to no treatment and the other moisturizers tested.

Olay® Advanced Healing Lotion

Olay® Advanced Healing Lotion


Were any of the findings unexpected?

While the moisturization benefits of niacinamide had been established through previous research, the sustained improvements in skin integrity after the final treatment demonstrated niacinamide’s ability to continually work within the skin’s surface, even if the product is not being used.

What should clinicians and patients take away from this study?

These findings demonstrate that cosmetic moisturizers formulated with niacinamide go beyond moisturization to improve the integrity of the stratum corneum for improved skin benefits over time. Furthermore, the speed benefit seen with the niacinamide/glycerin formulas of Olay® Advanced Healing Lotion and Olay Ultra Moisture Lotion can be attributed to niacinamide, as it has been shown to be a cosmetic ingredient with multiple benefits on aging skin appearance. As noted above, the sustained improvements in skin integrity after the final treatment also demonstrated that niacinamide containing products have the ability to continue to work within the skin’s surface, even if the product is not being used, much more effectively than other leading cosmetic moisturizers.

Olay® Ultra Moisture Lotion

Olay® Ultra Moisture Lotion

What recommendations do you have for future research as a result of your study?

P&G Beauty & Grooming continues to conduct research utilizing innovative technologies and unique combinations of ingredients, such as niacinamide and glycerin, to deliver benefits that improve skin barrier integrity over time.

Reference:
Two randomized, controlled, comparative studies of the stratum corneum integrity benefits of two cosmetic niacinamide/glycerin body moisturizers vs. conventional body moisturizers.

Christman JC, Fix DK, Lucus SC, Watson D, Desmier E, Wilkerson RJ, Fixler C.

The Procter & Gamble Company, Cincinnati, OH 45217, USA
J Drugs Dermatol. 2012 Jan;11(1):22-9.

The impact of subspecialization and dermatoscopy use on accuracy of melanoma diagnosis among primary care doctors in Australia: Author Interview

The impact of subspecialization and dermatoscopy use on accuracy of melanoma diagnosis among primary care doctors in Australia.

Author Interview: Cliff Rosendahl, MBBS

5 Larbonya Crescent, Capalaba 4157, Australia.
School of Medicine, The University of Queensland,
Herston, Brisbane, Queensland, Australia

What are the main findings of the study?

General practitioners who practiced exclusively in the field of skin cancer medicine biopsied/excised half as many benign lesions for each melanoma discovered compared to their generalist colleagues. This difference was highly significant when adjusted for other variables and means that the specificity of diagnosis for sub-specialised GPs was double that of their counterparts with respect to melanoma diagnosis.

Were any of the findings unexpected?

191 melanomas were diagnosed from 89,463 procedures performed to exclude non-melanoma skin cancer, and 10 melanomas were diagnosed from 3041 procedures in which there was no declared suspicion of malignancy.

This means that one in 468 lesions biopsied on suspicion of non-melanoma skin cancer was a  melanoma while one in 304 lesions, where there was no declared suspicion of malignancy (e.g. Cosmetic removal of dermal nevus or seborrheic keratosis), was a melanoma.

What should clinicians and patients take away from this study?

Our study showed that GPs who practised exclusively in the field of skin cancer medicine had a much higher overall commitment to the use of dermatoscopy. Because of this the improved specificity with dermatoscopy use in the sub-specialized group disappeared when adjusted for practitioner type. However we believe the association between dermatoscopy use and practitioner type is relevant. Trained dermatoscopy use should be promoted with respect to all GPs who treat skin cancer

What recommendations do you have for future research as a result of your study?

Our study was a robust evaluation of diagnostic specificity with respect to melanoma diagnosis in primary care. We did not make a precise measurement of overall diagnostic accuracy because that depends on both sensitivity and specificity of diagnosis. Sensitivity depends on how many melanomas are ‘missed’ and left on the patient and we cannot measure that.

A valid criticism of our study is that a high specificity, if coupled with a low sensitivity (i.e. diagnosis only of obvious or advanced disease), may be misleading as a measure of diagnostic accuracy.  Whilst we do not believe this to be the case with respect to this study we have acknowledged this limitation.

It is intended to further study what we regard as surrogate indicators of diagnostic sensitivity in this context.

Reference:

The impact of subspecialization and dermatoscopy use on accuracy of melanoma diagnosis among primary care doctors in Australia.

Rosendahl C, Williams G, Eley D, Wilson T, Canning G,
Keir J, McColl I, Wilkinson D.
J Am Acad Dermatol. 2012 Feb 9.

 

 

 

Inherited variants in the MC1R gene and survival from cutaneous melanoma: Author Interview

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study.

Author Interview:  Dr. Julia A Newton Bishop

Professor of Dermatology,
Section of Epidemiology and Biostatistics,
Leeds Institute of Molecular Medicine,
University of Leeds, Cancer Genetics Building,
St James’s University Hospital  Leeds, LS9 7TF

What are the main findings of the study?

This study was designed to look at whether inherited genetic variation in the MC1R gene influences survival from melanoma.

It was the first study performed by a new consortium called BioGenoMEL

(www.biogenomel.eu<http://www.biogenomel.eu>)

which was created to investigate inherited genes and their effects on survival.

The hypothesis is that people differ in how they interact with their cancers: that the genetic make up of some people makes it easier or harder for them to defend themselves against the tumor.

We chose MC1R to look at first because the MC1R gene is known to be very important in susceptibility to melanoma and because the way variations in the gene influences hair color and melanoma risk is via a protein called MiTF and MITF has effects on cell growth and DNA repair.

So the theory was that patients with red hair might be less likely to die as a result of their melanoma than those with dark hair.

The study produced good evidence that the theory was correct.

Were any of the findings unexpected?

No.

What should clinicians and patients take away from this study?

That there are differences in the host/tumor interaction for melanoma patients and by understanding these differences we will be able to understand survival better and hopefully treat melanoma better.

What recommendations do you have for future research as a result of your study?

That research in this field is important and is feasible.

Reference:

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study.

Davies JR, Randerson-Moor J, Kukalizch K, Harland M, Kumar R, Madhusudan S, Nagore E, Hansson J, Höiom V, Ghiorzo P, Gruis NA, Kanetsky PA, Wendt J, Pjanova D, Puig S, Saiag P, Schadendorf D, Soufir N, Okamoto I, Affleck P, García-Casado Z, Ogbah Z,Ozola A, Queirolo P, Sucker A, Barrett JH, van Doorn R, Bishop DT, Newton-Bishop J.

Pigment Cell Melanoma Res. 2012 Feb 10. doi: 10.1111/j.1755-148X.2012.00982.x.

New map pinpoints areas of highest human risk for lyme disease in eastern United States

Read the Author Interview here:  Maria Ana Diuk-Wasser PhD

Band of tick hunters gathered evidence for most extensive field study ever conducted. Given frequent over- and under-diagnosis of Lyme disease, map offers officials new tool for assessing risk and tracking disease spread

Deerfield, Ill. — A new map pinpoints well-defined areas of the Eastern United States where humans have the highest risk of contracting Lyme disease, one of the most rapidly emerging infectious diseases in North America, according to the U.S. Centers for Disease Control and Prevention. As part of the most extensive Lyme-related field study ever undertaken, researchers found high infection risk confined mainly to the Northeast, Mid-Atlantic and Upper Midwest and low risk in the South. The results were published in the February issue of the American Journal of Tropical Medicine and Hygiene. Given frequent over- and under-diagnosis of Lyme disease, the new map could arm the public and health officials with critical information on actual local risk.

“There has been a lot of discussion of whether Lyme disease exists outside of the Northeast and the upper Midwest, but our sampling of tick populations at hundreds of sites suggests that any diagnosis of Lyme disease in most of the South should be put in serious doubt, unless it involves someone who has traveled to an area where the disease is common,” said Dr. Maria A. Diuk-Wasser, Assistant Professor at the Yale School of Public Health and the lead author of the study.

“We can’t completely rule out the existence of Lyme disease in the South,” she added, “but it appears highly unlikely.”

The Lyme disease risk map was developed by researchers at the Yale School of Public Health in collaboration with Michigan State University, University of Illinois and University of California, Irvine, through a cooperative agreement with the CDC, which is seeking a better understanding of where Lyme disease poses a public health menace. Lyme disease is a tick-borne ailment with symptoms that range from a rash, headaches and fever to arthritis and Bell’s palsy.

Mobilizing Tick Hunters

The scientists involved in the study assembled a large field staff of more than 80 tick hunters. From 2004 to 2007, they combed through 304 individual sites from Maine to Florida and across the Midwest, dragging a one-meter by one-meter square of corduroy cloth in hopes of snagging the black legged tick Ixodes scapularis that is the main carrier of the Lyme disease pathogen, Borrelia burgdorferi. (The study did not examine risk in the West where Lyme disease is believed to be confined to areas along the Pacific Coast where a different tick species, known as Ixodes pacificus or the western blacklegged tick, carries Lyme.)

The goal of the field work was to provide doctors and public health officials with a better sense of where people are at risk of Lyme disease by using the presence of known Lyme-carrying ticks as the main indicator of danger.

Current geographical assessments of Lyme disease risk are heavily reliant on reports of human infections, which the study notes can be a poor predictor of risk. The researchers point out that using human cases to determine areas of risk can be misleading due to the high level of “underreporting and misdiagnosis” of Lyme disease. They also note that where someone is diagnosed with the disease is not necessarily where they contracted it.

In addition, the study found that infected I. scapularis ticks may colonize a region long before they actually infect a human with Lyme disease, which means risk can be significant even without a confirmed case.

“A better understanding of where Lyme disease is likely to be endemic is a significant factor in improving prevention, diagnosis and treatment,” Diuk-Wasser said. “People need to know where to take precautions to avoid tick bites. Also, doctors may be less likely to suspect and test for Lyme disease if they are unaware a patient was in a risky area and, conversely, they may act too aggressively and prescribe unneeded and potentially dangerous treatments if they incorrectly believe their patient was exposed to the pathogen.”

The study notes that “accurate and timely” diagnosis is crucial to initiating antibiotic treatments that can help patients avoid the more serious complications of Lyme disease. At the same time, the authors point out that incorrectly suspecting Lyme disease has its own consequences, including potentially life-threatening complications from the antibiotics typically used to treat infections. (While the laboratory test for Lyme disease can produce both false-positives and false-negatives, false-positives are far more likely in non-endemic areas.)

Establishing a Map for Lyme Disease Risk in the Eastern United States

The maps that emerged from the tick survey show a clear risk of Lyme disease in large parts of the Northeast (including eastern Pennsylvania) from Maine going as far south as Maryland and northern Virginia, which is in the Washington, DC, metropolitan area. But while conditions could be favorable for the disease to spread into the Tidewater region of Virginia – the data collected for the study indicates the bulk of the South is free of Lyme disease-carrying ticks.

The researchers also identify a separate and distinct Lyme disease risk region in the upper Midwest. It includes most of Wisconsin, a large area in northern Minnesota, and a sliver of northern Illinois.

However, the scientists confirm that Lyme disease remains on the move as its preference for forests and deer is aided by a century-long re-planting of trees inland once cleared for agriculture, along with a resurgence of deer populations. Diuk-Wasser and her colleagues found evidence to support an “emerging risk” for Lyme disease along the Illinois/Indiana border, the New York/Vermont border, southwestern Michigan, and eastern North Dakota. Also, Diuk-Wasser said new, unpublished field work now underway indicates Lyme disease is probably moving into central Virginia.

Lyme Disease: the Southern Challenge

While the scientists involved in mapping the Lyme disease risk believe most of the South is relatively free of the disease, one challenge to delineating a southern risk frontier is the fact that there are I. scapularis ticks in the region. They were once thought to be a distinct species, Diuk-Wasser said, but scientists now consider them to be the same species, although there are biological differences.

Map of regions where Lyme Disease-Carrying Ticks are most prevalent and Risk of Human Lyme Disease greatest from Yale School of Public Health

Map of regions where Lyme Disease-Carrying Ticks are most prevalent and Risk of Human Lyme Disease greatest. From Yale School of Public Health

Most notably, tick experts find the Southern I. scapularis exhibit a feeding behavior in the immature stages that is different than that of its northern cousins. The Southern ticks prefer, it appears, the blood of lizards and skinks to small mammals that are more likely to carry the bacteria and show no interest in feeding on humans, which scientists believe makes it unlikely they play an important role as Lyme disease carriers.

Diuk-Wasser noted that one reason some people in the South may believe Lyme disease is a risk in their region is that they may frequently encounter a species known as the lone star tick (Amblyomma americanum) that is “very aggressive, very abundant” and whose bite can cause a rash that looks similar to the “bull’s eye” lesion caused by Lyme disease. However, this disease, known as Southern Tick-Associated Rash Illness or STARI, does not feature the neurological and arthritis problems associated with Lyme disease.

Nonetheless, Diuk-Wasser stresses that scientists cannot rule out completely that Lyme disease exists outside of the areas identified in the mapping project. And she pointed out there are limitations to the tick sampling techniques she and her colleagues employed to create the risk map. For example, the field teams conducted their tick collecting in late May, June, July, and August, which is considered peak feeding time. But she said some areas might experience a population surge in early May or earlier. (The climate in April in parts of Tennessee is likely tick friendly, but Diuk-Wasser said other field studies conducted in Tennessee during the spring have not found any Lyme-infected ticks.)

“This is a useful tool that can help physicians, nurses and policymakers make realistic resource decisions,” said James W. Kazura, MD, President of the American Society of Tropical Medicine and Hygiene, which publishes the journal, and director of the Center for Global Health and Diseases at Case Western Reserve University. “The scientific research done to create this new risk map for Lyme disease is an example of what is needed in the U.S. today for a variety of diseases given its immense value in making clinical decisions and allocating scarce resources.”

Source:
American Society of Tropical Medicine and Hygiene  on Eurekalert